Prognostic implications of N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T in EMPEROR-Preserved
Background - N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) are associated with disease severity and outcomes among patients with heart failure (HF) with preserved ejection fraction. - Objectives - The authors evaluated associations between bo...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
July 2022
|
| In: |
JACC Heart failure
Year: 2022, Jahrgang: 10, Heft: 7, Pages: 512-524 |
| ISSN: | 2213-1787 |
| DOI: | 10.1016/j.jchf.2022.05.004 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jchf.2022.05.004 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S221317792200302X 
|
| Verfasserangaben: | James L. Januzzi, Javed Butler, Faiez Zannad, Gerasimos Filippatos, João Pedro Ferreira, Stuart J. Pocock, Naveed Sattar, Subodh Verma, Ola Vedin, Tomoko Iwata, Martina Brueckmann, Milton Packer, Stefan D. Anker, on behalf of the EMPEROR-Preserved Trial Study Group |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1871458684 | ||
| 003 | DE-627 | ||
| 005 | 20240331080331.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231128s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jchf.2022.05.004 |2 doi | |
| 035 | |a (DE-627)1871458684 | ||
| 035 | |a (DE-599)KXP1871458684 | ||
| 035 | |a (OCoLC)1425216308 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Januzzi, James L. |e VerfasserIn |0 (DE-588)1072418320 |0 (DE-627)827470649 |0 (DE-576)433842172 |4 aut | |
| 245 | 1 | 0 | |a Prognostic implications of N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T in EMPEROR-Preserved |c James L. Januzzi, Javed Butler, Faiez Zannad, Gerasimos Filippatos, João Pedro Ferreira, Stuart J. Pocock, Naveed Sattar, Subodh Verma, Ola Vedin, Tomoko Iwata, Martina Brueckmann, Milton Packer, Stefan D. Anker, on behalf of the EMPEROR-Preserved Trial Study Group |
| 264 | 1 | |c July 2022 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 1 June 2022, Artikelversion: 27 June 2022 | ||
| 500 | |a Gesehen am 28.11.2023 | ||
| 520 | |a Background - N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) are associated with disease severity and outcomes among patients with heart failure (HF) with preserved ejection fraction. - Objectives - The authors evaluated associations between both biomarkers and clinical outcomes in the EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction) trial. - Methods - Of 5,988 study participants, 5,986 (99.9%) and 5,825 (97.3%) had available baseline NT-proBNP and hs-cTnT; postbaseline NT-proBNP was also available. Baseline characteristics were expressed by biomarker quartiles. The effect of empagliflozin on cardiovascular death/ HF hospitalization, the individual components, total HF hospitalizations, slope of decline of estimated glomerular filtration rate (eGFR), and a composite renal endpoint were examined across biomarker quartiles. Change in NT-proBNP across study visits as a function of treatment assignment was also assessed. - Results - Higher baseline NT-proBNP and hs-cTnT concentrations were associated with more comorbidities and worse HF severity. Incidence rates for cardiac and renal outcomes were 2- to 5-fold higher among those in the highest vs lowest NT-proBNP or hs-cTnT quartiles. Empagliflozin consistently reduced the risk for cardiovascular events and reduced slope of eGFR decline across NT-proBNP or hs-cTnT quartiles. Empagliflozin treatment modestly lowered NT-proBNP; by 100 weeks, the adjusted mean difference in NT-proBNP from placebo was 7%. Increase in NT-proBNP from baseline to 12 weeks was strongly associated with risk of cardiovascular death/HF hospitalization. - Conclusions - The benefit of empagliflozin on cardiac outcomes and decline of eGFR is preserved across the wide range of baseline NT-proBNP and hs-cTnT evaluated. Empagliflozin modestly reduces NT-proBNP in HF with preserved ejection fraction. (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction [EMPEROR-Preserved]; NCT03057951) | ||
| 650 | 4 | |a empagliflozin | |
| 650 | 4 | |a heart failure | |
| 650 | 4 | |a high-sensitivity cardiac troponin (hs-cTn) | |
| 650 | 4 | |a N-terminal pro-B-type natriuretic peptide (NT-proBNP) | |
| 650 | 4 | |a prognosis | |
| 700 | 1 | |a Butler, Javed |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zannad, Faiez |e VerfasserIn |4 aut | |
| 700 | 1 | |a Filippatos, Gerasimos |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ferreira, João Pedro |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pocock, Stuart J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sattar, Naveed |e VerfasserIn |4 aut | |
| 700 | 1 | |a Verma, Subodh |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vedin, Ola |e VerfasserIn |4 aut | |
| 700 | 1 | |a Iwata, Tomoko |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brückmann, Martina |d 1970- |e VerfasserIn |0 (DE-588)121145069 |0 (DE-627)705257290 |0 (DE-576)292557736 |4 aut | |
| 700 | 1 | |a Packer, Milton |e VerfasserIn |4 aut | |
| 700 | 1 | |a Anker, Stefan D. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |a American College of Cardiology |t JACC Heart failure |d Amsterdam [u.a.] : Elsevier, 2013 |g 10(2022), 7 vom: Juli, Seite 512-524 |h Online-Ressource |w (DE-627)73770232X |w (DE-600)2705621-1 |w (DE-576)379733455 |x 2213-1787 |7 nnas |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g number:7 |g month:07 |g pages:512-524 |g extent:13 |a Prognostic implications of N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T in EMPEROR-Preserved |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jchf.2022.05.004 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S221317792200302X |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20231128 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 121145069 |a Brückmann, Martina |m 121145069:Brückmann, Martina |d 60000 |e 60000PB121145069 |k 0/60000/ |p 11 | ||
| 999 | |a KXP-PPN1871458684 |e 4419427787 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1871458684","physDesc":[{"extent":"13 S."}],"id":{"doi":["10.1016/j.jchf.2022.05.004"],"eki":["1871458684"]},"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"given":"James L.","role":"aut","roleDisplay":"VerfasserIn","family":"Januzzi","display":"Januzzi, James L."},{"roleDisplay":"VerfasserIn","display":"Butler, Javed","family":"Butler","role":"aut","given":"Javed"},{"display":"Zannad, Faiez","family":"Zannad","roleDisplay":"VerfasserIn","role":"aut","given":"Faiez"},{"given":"Gerasimos","role":"aut","display":"Filippatos, Gerasimos","family":"Filippatos","roleDisplay":"VerfasserIn"},{"given":"João Pedro","role":"aut","roleDisplay":"VerfasserIn","display":"Ferreira, João Pedro","family":"Ferreira"},{"roleDisplay":"VerfasserIn","display":"Pocock, Stuart J.","family":"Pocock","role":"aut","given":"Stuart J."},{"roleDisplay":"VerfasserIn","display":"Sattar, Naveed","family":"Sattar","given":"Naveed","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Verma, Subodh","family":"Verma","role":"aut","given":"Subodh"},{"role":"aut","given":"Ola","roleDisplay":"VerfasserIn","display":"Vedin, Ola","family":"Vedin"},{"given":"Tomoko","role":"aut","display":"Iwata, Tomoko","family":"Iwata","roleDisplay":"VerfasserIn"},{"family":"Brückmann","display":"Brückmann, Martina","roleDisplay":"VerfasserIn","given":"Martina","role":"aut"},{"given":"Milton","role":"aut","roleDisplay":"VerfasserIn","family":"Packer","display":"Packer, Milton"},{"roleDisplay":"VerfasserIn","display":"Anker, Stefan D.","family":"Anker","given":"Stefan D.","role":"aut"}],"title":[{"title":"Prognostic implications of N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T in EMPEROR-Preserved","title_sort":"Prognostic implications of N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T in EMPEROR-Preserved"}],"note":["Online verfügbar: 1 June 2022, Artikelversion: 27 June 2022","Gesehen am 28.11.2023"],"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"July 2022"}],"relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 10.09.2025"],"title":[{"title_sort":"JACC Heart failure","subtitle":"a journal of the American College of Cardiology","title":"JACC Heart failure"}],"recId":"73770232X","id":{"issn":["2213-1787"],"zdb":["2705621-1"],"eki":["73770232X"]},"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"part":{"volume":"10","pages":"512-524","year":"2022","text":"10(2022), 7 vom: Juli, Seite 512-524","extent":"13","issue":"7"},"corporate":[{"roleDisplay":"VerfasserIn","display":"American College of Cardiology","role":"aut"}],"origin":[{"dateIssuedDisp":"2013-","publisher":"Elsevier ; American College of Cardiology Foundation","dateIssuedKey":"2013","publisherPlace":"Amsterdam [u.a.] ; New York, NY"}],"pubHistory":["1.2013 -"],"disp":"American College of CardiologyJACC Heart failure"}],"name":{"displayForm":["James L. Januzzi, Javed Butler, Faiez Zannad, Gerasimos Filippatos, João Pedro Ferreira, Stuart J. Pocock, Naveed Sattar, Subodh Verma, Ola Vedin, Tomoko Iwata, Martina Brueckmann, Milton Packer, Stefan D. Anker, on behalf of the EMPEROR-Preserved Trial Study Group"]}} | ||
| SRT | |a JANUZZIJAMPROGNOSTIC2022 | ||